{"transactions":[{"id":676280,"issuer":{"id":6324,"kind":"organization","name":"NovaBridge Biosciences","symbol":"NBP"},"owners":[{"id":19968,"kind":"person","name":"Lenz Robert A.","position":1,"cik":"0001992908","reported_name":"Lenz Robert A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Share Units","published_at":"2026-08-25T20:15:13.000Z","date":"2026-08-22","kind":"exercise","planned":false,"acquired":false,"shares":7486,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ADS."},{"field":"shares","element":"transactionShares","label":"F4","text":"Reported securities represent ADSs."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On August 22, 2025, the Reporting Person was granted 22,460 restricted share units (\"RSUs\"). The RSUs vested or shall vest over three years in three equal annual installments on August 22, 2026, 2027 and 2028."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"On August 22, 2025, the Reporting Person was granted 22,460 restricted share units (\"RSUs\"). The RSUs vested or shall vest over three years in three equal annual installments on August 22, 2026, 2027 and 2028."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Reported securities represent ADSs."}],"balance_after":14974,"derivative":{"underlying":"Ordinary Shares","underlying_shares":7486},"source":{"system":"sec-edgar","filing":"0001992908-26-000013","document":"form4-08252026_040807.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1992908/000199290826000013/form4-08252026_040807.xml","form_type":"4"}},{"id":676279,"issuer":{"id":6324,"kind":"organization","name":"NovaBridge Biosciences","symbol":"NBP"},"owners":[{"id":19968,"kind":"person","name":"Lenz Robert A.","position":1,"cik":"0001992908","reported_name":"Lenz Robert A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2026-08-25T20:15:13.000Z","date":"2026-08-22","kind":"exercise","planned":false,"acquired":true,"shares":17218,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares (\"ADS\"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"Reported securities are represented by 7,486 ADSs."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ADS."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reported securities are represented by 7,486 ADSs."}],"balance_after":17218,"source":{"system":"sec-edgar","filing":"0001992908-26-000013","document":"form4-08252026_040807.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1992908/000199290826000013/form4-08252026_040807.xml","form_type":"4"}},{"id":748283,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":19968,"kind":"person","name":"Lenz Robert A.","position":1,"cik":"0001992908","reported_name":"Lenz Robert A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-05T21:26:45.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Includes an option award for 2,500 shares pursuant to the Issuer's non-employee director compensation policy which represents a prorated annual grant for the previous year."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"100% of the shares underlying the option vest on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":12500,"derivative":{"exercise_price":27.95,"expiration_date":"2036-06-02","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001992908-26-000011","document":"form4-06052026_090641.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1992908/000199290826000011/form4-06052026_090641.xml","form_type":"4"}},{"id":851367,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":19968,"kind":"person","name":"Lenz Robert A.","position":1,"cik":"0001992908","reported_name":"Lenz Robert A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-10T20:19:34.000Z","date":"2026-03-06","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option award shall vest in three (3) equal annual installments on March 6, 2027, March 6, 2028 and March 6, 2029, subject to the Reporting Person's continuous service through each such date."}],"balance_after":20000,"derivative":{"exercise_price":23.78,"expiration_date":"2036-03-05","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001992908-26-000007","document":"form4-03102026_080331.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1992908/000199290826000007/form4-03102026_080331.xml","form_type":"4"}},{"id":1256220,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":19968,"kind":"person","name":"Lenz Robert A.","position":1,"cik":"0001992908","reported_name":"Lenz Robert A.","relationship":{"officer":true,"officer_title":"Head of R&D"}}],"security":"Common Stock","published_at":"2025-02-20T22:12:34.000Z","date":"2025-02-18","kind":"sale","planned":true,"acquired":false,"shares":5614,"price":1.6714,"value":9383.2396,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on June 12, 2024, which provides for the automatic sale of shares of common stock that would otherwise be issuable on each vesting date of a covered restricted stock unit in an amount necessary to satisfy the applicable withholding obligation."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades in prices ranging from $1.66 to $1.695, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":309092,"source":{"system":"sec-edgar","filing":"0001610717-25-000028","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1992908/000161071725000028/form4.xml","form_type":"4"}},{"id":1264274,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":19968,"kind":"person","name":"Lenz Robert A.","position":1,"cik":"0001992908","reported_name":"Lenz Robert A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Head of R&D"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-18T21:30:08.000Z","date":"2025-02-13","kind":"grant","planned":false,"acquired":true,"shares":100000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Effective February 13, 2025, subject to and contingent on the approval by the Issuer's stockholders, the Board approved an option repricing with an exercise price of $1.69 per share (the \"Repricing\") of the outstanding stock options held by members of the Board, certain employees and other service providers, provided that if the requisite approval of the Issuer's stockholders is not obtained, the Repricing will be void and the terms of each repriced option shall continue to be subject to its original terms and conditions, including, without limitation, the per share exercise price. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to the option vest on the first anniversary measured from February 14, 2024 (the \"Vesting Commencement Date\"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":100000,"derivative":{"exercise_price":1.69,"expiration_date":"2034-02-14","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000950170-25-022322","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1992908/000095017025022322/ownership.xml","form_type":"4"}},{"id":1264273,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":19968,"kind":"person","name":"Lenz Robert A.","position":1,"cik":"0001992908","reported_name":"Lenz Robert A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Head of R&D"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-18T21:30:08.000Z","date":"2025-02-13","kind":"grant","planned":false,"acquired":true,"shares":502934,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Effective February 13, 2025, subject to and contingent on the approval by the Issuer's stockholders, the Board approved an option repricing with an exercise price of $1.69 per share (the \"Repricing\") of the outstanding stock options held by members of the Board, certain employees and other service providers, provided that if the requisite approval of the Issuer's stockholders is not obtained, the Repricing will be void and the terms of each repriced option shall continue to be subject to its original terms and conditions, including, without limitation, the per share exercise price. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option vest on the first anniversary measured from September 11, 2023 (the \"Vesting Commencement Date\"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":502934,"derivative":{"exercise_price":1.69,"expiration_date":"2033-09-14","underlying":"Common Stock","underlying_shares":502934},"source":{"system":"sec-edgar","filing":"0000950170-25-022322","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1992908/000095017025022322/ownership.xml","form_type":"4"}},{"id":1264272,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":19968,"kind":"person","name":"Lenz Robert A.","position":1,"cik":"0001992908","reported_name":"Lenz Robert A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Head of R&D"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-18T21:30:08.000Z","date":"2025-02-13","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":100000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to the option vest on the first anniversary measured from February 14, 2024 (the \"Vesting Commencement Date\"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":0,"derivative":{"exercise_price":18.07,"expiration_date":"2034-02-14","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000950170-25-022322","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1992908/000095017025022322/ownership.xml","form_type":"4"}},{"id":1264271,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":19968,"kind":"person","name":"Lenz Robert A.","position":1,"cik":"0001992908","reported_name":"Lenz Robert A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Head of R&D"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-18T21:30:08.000Z","date":"2025-02-13","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":502934,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option vest on the first anniversary measured from September 11, 2023 (the \"Vesting Commencement Date\"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":0,"derivative":{"exercise_price":17,"expiration_date":"2033-09-14","underlying":"Common Stock","underlying_shares":502934},"source":{"system":"sec-edgar","filing":"0000950170-25-022322","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1992908/000095017025022322/ownership.xml","form_type":"4"}},{"id":1387663,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":19968,"kind":"person","name":"Lenz Robert A.","position":1,"cik":"0001992908","reported_name":"Lenz Robert A.","relationship":{"officer":true,"officer_title":"Head of R&D"}}],"security":"Common Stock","published_at":"2024-10-11T20:10:14.000Z","date":"2024-10-10","kind":"sale","planned":true,"acquired":false,"shares":8260,"price":15.0851,"value":124602.926,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on June 12, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades in prices ranging from $15.00 to 15.2435, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":314706,"source":{"system":"sec-edgar","filing":"0001610717-24-000505","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1992908/000161071724000505/form4.xml","form_type":"4"}},{"id":1387662,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":19968,"kind":"person","name":"Lenz Robert A.","position":1,"cik":"0001992908","reported_name":"Lenz Robert A.","relationship":{"officer":true,"officer_title":"Head of R&D"}}],"security":"Common Stock","published_at":"2024-10-11T20:10:14.000Z","date":"2024-10-09","kind":"sale","planned":true,"acquired":false,"shares":5563,"price":15.0112,"value":83507.3056,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on June 12, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades in prices ranging from $15.00 to $15.065, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":322966,"source":{"system":"sec-edgar","filing":"0001610717-24-000505","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1992908/000161071724000505/form4.xml","form_type":"4"}},{"id":1402596,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":19968,"kind":"person","name":"Lenz Robert A.","position":1,"cik":"0001992908","reported_name":"Lenz Robert A.","relationship":{"officer":true,"officer_title":"Head of R&D"}}],"security":"Common Stock","published_at":"2024-09-19T20:35:50.000Z","date":"2024-09-18","kind":"sale","planned":true,"acquired":false,"shares":10676,"price":12.0917,"value":129090.9892,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on June 12, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades in prices ranging from $12.00 to $12.18, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":328529,"source":{"system":"sec-edgar","filing":"0001610717-24-000490","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1992908/000161071724000490/form4.xml","form_type":"4"}},{"id":1402595,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":19968,"kind":"person","name":"Lenz Robert A.","position":1,"cik":"0001992908","reported_name":"Lenz Robert A.","relationship":{"officer":true,"officer_title":"Head of R&D"}}],"security":"Common Stock","published_at":"2024-09-19T20:35:50.000Z","date":"2024-09-17","kind":"sale","planned":true,"acquired":false,"shares":30788,"price":11.8142,"value":363735.5896,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on June 12, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades in prices ranging from $11.5985 to $12.08, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":339205,"source":{"system":"sec-edgar","filing":"0001610717-24-000490","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1992908/000161071724000490/form4.xml","form_type":"4"}},{"id":1406835,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":19968,"kind":"person","name":"Lenz Robert A.","position":1,"cik":"0001992908","reported_name":"Lenz Robert A.","relationship":{"officer":true,"officer_title":"Head of R&D"}}],"security":"Common Stock","published_at":"2024-09-16T20:05:48.000Z","date":"2024-09-12","kind":"sale","planned":true,"acquired":false,"shares":32948,"price":11.4321,"value":376664.8308,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on June 12, 2024 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades in prices ranging from $11.22 to $11.6050, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":369993,"source":{"system":"sec-edgar","filing":"0001610717-24-000478","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1992908/000161071724000478/form4.xml","form_type":"4"}},{"id":1638678,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":19968,"kind":"person","name":"Lenz Robert A.","position":1,"cik":"0001992908","reported_name":"Lenz Robert A.","relationship":{"officer":true,"officer_title":"Head of R&D"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-16T21:13:03.000Z","date":"2024-02-14","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to the option vest on the first anniversary measured from February 14, 2024 (the \"Vesting Commencement Date\"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":100000,"derivative":{"exercise_price":18.07,"expiration_date":"2034-02-13","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001610717-24-000063","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1992908/000161071724000063/form4.xml","form_type":"4"}},{"id":1638677,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":19968,"kind":"person","name":"Lenz Robert A.","position":1,"cik":"0001992908","reported_name":"Lenz Robert A.","relationship":{"officer":true,"officer_title":"Head of R&D"}}],"security":"Common Stock","published_at":"2024-02-16T21:13:03.000Z","date":"2024-02-14","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Constitute restricted stock units (\"RSUs\") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 25% of the RSUs vest annually measured from February 14, 2024 (the \"Vesting Commencement Date\"), such that 100% of the RSUs will be fully vested on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":402941,"source":{"system":"sec-edgar","filing":"0001610717-24-000063","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1992908/000161071724000063/form4.xml","form_type":"4"}},{"id":1779193,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":19968,"kind":"person","name":"Lenz Robert A.","position":1,"cik":"0001992908","reported_name":"Lenz Robert A.","relationship":{"officer":true,"officer_title":"Head of R&D"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-09-18T21:58:10.000Z","date":"2023-09-14","kind":"grant","planned":false,"acquired":true,"shares":502934,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to the option vest on the first anniversary measured from September 11, 2023 (the \"Vesting Commencement Date\"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":502934,"derivative":{"exercise_price":17,"expiration_date":"2033-09-13","underlying":"Common Stock","underlying_shares":502934},"source":{"system":"sec-edgar","filing":"0001610717-23-000286","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1992908/000161071723000286/form4.xml","form_type":"4"}},{"id":1779192,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":19968,"kind":"person","name":"Lenz Robert A.","position":1,"cik":"0001992908","reported_name":"Lenz Robert A.","relationship":{"officer":true,"officer_title":"Head of R&D"}}],"security":"Common Stock","published_at":"2023-09-18T21:58:10.000Z","date":"2023-09-14","kind":"grant","planned":false,"acquired":true,"shares":352941,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Constitute restricted stock units (\"RSUs\") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/4th of the RSUs vest annually on September 11 of each year, with the first 1/4th vesting on September 11, 2024."}],"balance_after":352941,"source":{"system":"sec-edgar","filing":"0001610717-23-000286","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1992908/000161071723000286/form4.xml","form_type":"4"}}]}